Emerging Advances in Neuropharmacology: Novel Therapeutic Targets for Neurodegenerative Disorders
Current Pharmaceutical Research · 14.08.2026 · 271-291
DOI: 10.63785/cpr.2026.2.2.271291 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Pharmaceutical Research, online erschienen am 14.08.2026. Verfasst von Nisha und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Neurodegenerative diseases are a heterogeneous group of chronic and progressive disorders, which are characterized by selective neuronal destruction, synaptic malfunction and progressive cognitive and locomotor dysfunction. The major ones are Alzheimer disease, Parkinson disease, Huntington disease, and amyotrophic lateral sclerosis which are a formidable and growing global health and socio-economic burden mainly due to demographic aging. Even despite the advances in the symptomatic treatment, predominantly through the cholinergic, dopaminergic, glutamatergic, and GABAergic system, the current treatment regimens are not able to stop the underlying neurodegenerative events or reverse them. There is mounting evidence that convergent pathogenic mechanisms, such as protein misfolding and aggregation, oxidative stress, mitochondrial dysfunction, impaired autophagy-lysosomal pathways, synaptic dysfunction, and chronic neuroinflammation, are convergent mechanisms. These convergent molecular and cellular cascades provide a strong rationale behind the identification of new neuropharmacological targets, which include: kinases, phosphatases, epigenetic regulators, neurotrophic signalling pathways and neuroimmune mediators. Advances in the biomarker discovery, genomics and systems biology have further enabled the use of precision based therapeutic stratification and early-intervention approaches. Genetic, nanotechnology, and RNA-based therapeutics as well as biologics are reconfiguring translational models in neurodegeneration. A mechanism-based, multi-target, precision neuropharmacological approach, as a group, has significant potential in achieving long-term neuroprotection, improved clinical and disease modification in neurodegenerative diseases.
Zitieren
APA
Nisha, & Qadir, S. (2026). Emerging Advances in Neuropharmacology: Novel Therapeutic Targets for Neurodegenerative Disorders. Current Pharmaceutical Research, 271-291. https://doi.org/10.63785/cpr.2026.2.2.271291
Vancouver
Nisha, Qadir S. Emerging Advances in Neuropharmacology: Novel Therapeutic Targets for Neurodegenerative Disorders. Current Pharmaceutical Research. 2026:271-291. doi:10.63785/cpr.2026.2.2.271291
BibTeX
@article{Nisha2026,
author = {Nisha and Qadir, Sumairah},
title = {Emerging Advances in Neuropharmacology: Novel Therapeutic Targets for Neurodegenerative Disorders},
journal = {Current Pharmaceutical Research},
year = {2026},
pages = {271--291},
doi = {10.63785/cpr.2026.2.2.271291}
}
EUVIMED